Novavax Shares Plunge on Report of Covid-19 Vaccine Manufacturing Problems

A new report in Politico cast further doubt on the Novavax vaccine’s effectiveness. Politico said the methods the company uses to test the purity of its vaccine have fallen short of regulators’ standards, with the publication citing multiple people familiar with Novavax’s difficulties. Novavax issued a statement Wednesday saying it expects to complete ongoing regulatory submissions over the next few weeks in the U.K., Europe and Canada. It said it has already filed for authorization in India and for emergency use with the World Health Organization. The company said it plans to file its vaccine for emergency-use authorization in the U.S. by the end of 2021.